Red Blood Cell Transfusion in Patients With Autoantibodies: Is It Effective and Safe Without Increasing Hemolysis Risk?
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background: The therapeutic efficacy of red blood cell (RBC) transfusions in patients with autoimmune hemolytic anemia (AIHA) is highly debated because of speculations on the increased risk of transfusion reactions; yet it is a suggested adjuvant therapy in anemic patients with life-threatening hypoxemia. In this study, we evaluated the safety and efficacy of RBC transfusions in AIHA patients. Methods: Daily changes in hemoglobin, total bilirubin, and lactate dehydrogenase (LDH) were assessed in 161 AIHA patients without bleeding history who were transfused once with 1-5 units of the least-incompatible RBCs and monitored over a seven-day period. Post-transfusion patients positive for alloantibodies only or those without RBC-specific antibodies were considered as control groups (N=100 for both groups). Results: The three groups revealed similar increases in hemoglobin of 1.40-1.70 g/dL (autoantibodies), 1.20-1.60 g/dL (alloantibodies only), and 1.40-1.55 g/dL (no antibodies) for seven days following transfusion of 10 mL RBCs/kg. During follow-up, no significant changes in total bilirubin or LDH levels were detected in the AIHA group compared with controls. Influences due to autoantibody type, direct antiglobulin test (DAT) specificity and strength, and steroid therapy status on transfusion reactions were not evident in AIHA patients. In addition, changes in hemoglobin levels were significantly higher (P<0.001) in severe anemia (<5 g/dL) than in other patients. Conclusions: Transfusion of the least-incompatible RBCs in AIHA patients is effective and safe without any associated increase in hemolysis risk when compared with post-transfusion patients positive for alloantibodies or those lacking RBC-specific antibodies.
Abstract
Background: The therapeutic efficacy of red blood cell (RBC) transfusions in patients with autoimmune hemolytic anemia (AIHA) is highly debated because of speculations on the increased risk of transfusion reactions; yet it is a suggested adjuvant therapy in anemic patients with life-threatening hypoxemia. In this study, we evaluated the safety and efficacy of RBC transfusions in AIHA patients. Methods: Daily changes in hemoglobin, total bilirubin, and lactate dehydrogenase (LDH) were assessed in 161 AIHA patients without bleeding history who were transfused once with 1-5 units of the least-incompatible RBCs and monitored over a seven-day period. Post-transfusion patients positive for alloantibodies only or those without RBC-specific antibodies were considered as control groups (N=100 for both groups). Results: The three groups revealed similar increases in hemoglobin of 1.40-1.70 g/dL (autoantibodies), 1.20-1.60 g/dL (alloantibodies only), and 1.40-1.55 g/dL (no antibodies) for seven days following transfusion of 10 mL RBCs/kg. During follow-up, no significant changes in total bilirubin or LDH levels were detected in the AIHA group compared with controls. Influences due to autoantibody type, direct antiglobulin test (DAT) specificity and strength, and steroid therapy status on transfusion reactions were not evident in AIHA patients. In addition, changes in hemoglobin levels were significantly higher (P<0.001) in severe anemia (<5 g/dL) than in other patients. Conclusions: Transfusion of the least-incompatible RBCs in AIHA patients is effective and safe without any associated increase in hemolysis risk when compared with post-transfusion patients positive for alloantibodies or those lacking RBC-specific antibodies.
참고문헌 (15)
- Packman CH, "Hemolytic anemia due to warm autoantibodies", Blood Rev, 22, pp.17~31 (2008)
- Barros MM, "Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment", Transfus Med Rev, 24, pp.195~210 (2010)
- Gehrs BC, "Autoimmune hemolytic anemia", Am J Hematol, 69, pp.258~271 (2002)
- Reardon JE, "Laboratory evaluation and transfusion support of patients with autoimmune hemolytic anemia", Am J Clin Pathol, 125(S), pp.S71~77 (2006)
- Wheeler CA, "Warm reactive autoantibodies: clinical and serologic correlations", Am J Clin Pathol, 122, pp.680~685 (2004)
- Roback JD, "Technical manual", pp.511~ (2008), American Association of Blood Banks
- Hillyer CD, "Blood banking and transfusion medicine", pp.560~561 (2007), Elsevier
- Salama A, "Red blood cell transfusion in warm-type autoimmune haemolytic anaemia", Lancet, 340, pp.1515~1517 (1992)
- Petz LD, "A physician’s guide to transfusion in autoimmune haemolytic anaemia", Br J Haematol, 124, pp.712~716 (2004)
- Leger RM, "Evaluation of methods for detecting alloantibodies underlying warm autoantibodies", Transfusion, 39, pp.11~16 (1999)
- King KE, "Treatment of autoimmune hemolytic anemia", Semin Hematol, 42, pp.131~136 (2005)
- Viele MK, "What can we learn about the need for transfusion from patients who refuse blood? The experience with Jehovah’s Witnesses", Transfusion, 34, pp.396~401 (1994)
- Wikman A, "Characterization of red cell autoantibodies in consecutive DAT-positive patients with relation to in vivo haemolysis", Ann Hematol, 84, pp.150~158 (2005)
- Garratty G, "Correlation between in vivo hemolysis and the amount of red cell-bound IgG measured by flow cytometry", Transfusion, 30, pp.617~621 (1990)
- Garratty G, "The James Blundell Award Lecture 2007: do we really understand immune red cell destruction?", Transfus Med, 18, pp.321~334 (2008)